RESUMO
Acne vulgaris is a common dermatological diagnosis observed in pediatric patients with skin of color, often resulting in scarring, keloid formation, and post-inflammatory hyperpigmentation, significantly impacting their quality of life. This exploratory retrospective chart review included 77 black pediatric patients seen at a tertiary care center for acne vulgaris between 2018 and 2023. We analyzed demographics, acne descriptors, and treatment modalities. The most common acne morphology was comedonal acne (83.6%), with 71% of the patients being female. Significant age differences were observed particularly for acne at the chin and overall face. Treatment regimens commonly prescribed included combinations of adapalene and benzoyl peroxide (22%), topical antibiotics, tretinoin, and benzoyl peroxide (34%). Given the higher risk of sequelae for patients with darker skin, it is crucial to address their unique treatment needs. This study highlights the distinctive characteristics of acne in black pediatric patients and calls for further research to enhance our understanding and treatment of this population. Limitations include the lack of direct patient interactions and reliance on chart data. Further studies are needed to compare acne presentation in skin of color of other populations, refining our knowledge of acne clinical presentation, complications, and treatment modalities for diverse patient populations.
Assuntos
Acne Vulgar , Antibacterianos , Negro ou Afro-Americano , Fármacos Dermatológicos , Humanos , Acne Vulgar/tratamento farmacológico , Feminino , Criança , Masculino , Estudos Retrospectivos , Adolescente , Fármacos Dermatológicos/uso terapêutico , Antibacterianos/uso terapêutico , Peróxido de Benzoíla/uso terapêutico , Tretinoína/uso terapêutico , Fatores EtáriosRESUMO
BACKGROUND: Acne vulgaris poses significant physical and psychological challenges worldwide. Data of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) for acne treatment in Asian patients is limited. METHODS: In this randomized double-blind clinical trial, 49 Korean patients with moderate-to-severe acne and scars were assigned to the A0.3/BPO2.5 (N.=37) or vehicle (N.=12) group. Acne and acne scar severity scores were assessed at baseline and 4, 8, 12, and 24 weeks. The primary outcomes were treatment success rate (reduction of ≥2 Investigator's Global Assessment grade and reaching a grade of 0 or 1) and proportional acne lesion and scar count reduction against the baseline. To assess histological changes, 2-mm punch biopsies were performed at baseline and week 24 on the respective inflammatory lesions or scars. RESULTS: At week 24, the A0.3/BPO2.5 group had a significantly higher treatment success rate than the vehicle group. The total acne count, inflammatory lesion count, and non-inflammatory lesion count percentages (against baselines) with A0.3/BPO2.5 and the vehicle were 12.1% vs. 96.7%, 8.0% vs. 101.2%, and 13.3% vs. 98.9%, respectively (all P<0.001). Scar count percentages (against baselines) with A0.3/BPO2.5 and the vehicle were 27.3% and 96.5%, respectively (P<0.001). Significant elevations in collagen 1 and 3, elastin, CK15, and p63 levels, with increases of 172.7%, 230.6%, 176.5%, 286.2%, and 105.9%, respectively, in comparison to baseline (all P<0.05). No major adverse events leading to discontinuation were observed. CONCLUSIONS: A0.3/BPO2.5 was an effective and safe treatment for acne and acne scars in Asian patients supported by robust histopathological and immunohistochemical evidence.
Assuntos
Acne Vulgar , Adapaleno , Fármacos Dermatológicos , Géis , Humanos , Acne Vulgar/tratamento farmacológico , Acne Vulgar/patologia , Método Duplo-Cego , Feminino , Masculino , Fármacos Dermatológicos/uso terapêutico , República da Coreia , Adulto Jovem , Adulto , Adapaleno/uso terapêutico , Adapaleno/farmacologia , Adolescente , Imuno-Histoquímica , Peróxido de Benzoíla/uso terapêutico , Resultado do Tratamento , Cicatriz/patologia , Cicatriz/tratamento farmacológico , Índice de Gravidade de Doença , Combinação Adapaleno e Peróxido de Benzoil/uso terapêutico , Combinação Adapaleno e Peróxido de Benzoil/farmacologiaRESUMO
Benzoyl peroxide (BPO), as a widely used organic peroxide, has attracted widespread attention from all sectors of society for its environmental hazards and potential risks to human health. Herein, we employed a Förster resonance energy transfer (FRET) strategy to construct a novel ratiometric fluorescent probe CY-DCI for BPO detection in food, zebrafish, and mice. Specifically, a hemicyanine fluorophore and a dicyanoisophorone fluorophore were connected with a piperazine group as donor and acceptor, respectively, and an olefinic unsaturated bond as the reaction site. CY-DCI has favorable selectivity and an excellent detection limit as low as 58.1 nM, and the recovery rates for real-sample detection ranged from 95.8 % to 104 %, with relative standard deviations (RSD) less than 2.58 %. To further improve its practicality, silica gel plates and test strips containing CY-DCI (0-50 µM) were developed for naked-eye detection of BPO with satisfactory results. Additionally, this novel probe was then applied for ratiometric imaging of living zebrafish and mice and showed high ratiometric imaging resolution in the green and red channels, thus demonstrating its practical application for BPO detection and toxicity early warning in food and biosystems.
Assuntos
Peróxido de Benzoíla , Corantes Fluorescentes , Contaminação de Alimentos , Peixe-Zebra , Animais , Corantes Fluorescentes/química , Corantes Fluorescentes/toxicidade , Peróxido de Benzoíla/toxicidade , Peróxido de Benzoíla/análise , Peróxido de Benzoíla/química , Camundongos , Contaminação de Alimentos/análise , Transferência Ressonante de Energia de FluorescênciaRESUMO
Acne is a chronic, recurrent inflammatory condition of the pilosebaceous unit. It affects approximately 85% of adolescents and creates significant psychosocial and financial burdens. The pathogenesis involves altered follicular growth and differentiation, microbial colonization with Cutibacterium acnes, increased sebum production influenced by androgen levels, and inflammation. Evidence-based risk factors include family history and body mass index. Diagnosis of acne is clinical, according to patient age and acne morphology and severity. Setting treatment expectations is an important aspect of management. For mild acne, benzoyl peroxide is an effective first-line drug as monotherapy or in combination with a topical retinoid and/or topical antibiotic. Oral tetracyclines are first-line drugs as part of a multipart treatment regimen for moderate to severe acne for patients older than 8 years. Oral isotretinoin is the first-line drug for moderate to severe inflammatory acne. Because of its teratogenic effects, its prescribing is monitored through the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program. Prescribing oral or topical antibiotics as monotherapy for acne is not recommended, as this may increase microbial resistance. Combined oral contraceptives and spironolactone are used as adjunctive therapies in female adolescents. Patients with skin of color, pregnant patients, and transgender or gender diverse patients warrant special considerations in acne management.
Assuntos
Acne Vulgar , Antibacterianos , Fármacos Dermatológicos , Isotretinoína , Humanos , Acne Vulgar/tratamento farmacológico , Acne Vulgar/diagnóstico , Adolescente , Criança , Fármacos Dermatológicos/uso terapêutico , Antibacterianos/uso terapêutico , Isotretinoína/uso terapêutico , Feminino , Peróxido de Benzoíla/uso terapêutico , Fatores de Risco , Masculino , Espironolactona/uso terapêutico , Retinoides/uso terapêuticoRESUMO
BACKGROUND: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose triple-combination approved for the treatment of acne. This post hoc analysis investigated the efficacy and safety of CAB in pediatric (<18 years) and adult (greater than or equal to 18 years) participants. METHODS: In two multicenter, double-blind, phase 3 studies (NCT04214639 and NCT04214652), participants greater than or equal to 9 years of age with moderate-to-severe acne were randomized (2:1) to 12 weeks of once-daily treatment with CAB or vehicle gel. Pooled data were analyzed for pediatric and adult subpopulations. Assessments included treatment success (greater than or equal to 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 0 [clear] or 1 [almost clear], inflammatory/noninflammatory lesion counts, Acne-Specific Quality of Life (Acne-QoL) questionnaire, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability. RESULTS: At week 12, treatment success rates for both pediatric and adult participants were significantly greater with CAB (52.7%; 45.9%) than with vehicle (24.0%; 23.5%; P<0.01, both). CAB-treated participants in both subgroups experienced greater reductions from baseline versus vehicle in inflammatory (pediatric: 78.6% vs 50.4%; adult: 76.6% vs 62.8%; P<0.001, both) and noninflammatory lesions (pediatric: 73.8% vs 41.1%; adult: 70.7% vs 52.2%; P<0.001, both). Acne-QoL improvements from baseline to week 12 were significantly greater with CAB than with a vehicle. Most TEAEs were of mild-to-moderate severity; no age-related trends for safety/tolerability were observed. Conclusions: CAB gel demonstrated comparable efficacy, quality of life improvements, and safety in pediatric and adult participants with moderate-to-severe acne. As the first fixed-dose, triple-combination topical formulation, CAB represents an important new treatment option for patients with acne. J Drugs Dermatol. 2024;23(6):394-402. doi:10.36849/JDD.8357.
Assuntos
Acne Vulgar , Peróxido de Benzoíla , Clindamicina , Fármacos Dermatológicos , Combinação de Medicamentos , Géis , Qualidade de Vida , Humanos , Acne Vulgar/tratamento farmacológico , Clindamicina/administração & dosagem , Clindamicina/efeitos adversos , Clindamicina/análogos & derivados , Criança , Método Duplo-Cego , Adolescente , Feminino , Masculino , Adulto , Peróxido de Benzoíla/administração & dosagem , Peróxido de Benzoíla/efeitos adversos , Resultado do Tratamento , Adulto Jovem , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/efeitos adversos , Administração Cutânea , Índice de Gravidade de DoençaAssuntos
Peróxido de Benzoíla , Aprovação de Drogas , Composição de Medicamentos , United States Food and Drug Administration , Humanos , Estados Unidos , Peróxido de Benzoíla/administração & dosagem , Composição de Medicamentos/métodos , Acne Vulgar/tratamento farmacológico , Fármacos Dermatológicos/administração & dosagem , Feminino , Satisfação do PacienteRESUMO
In this work, based on the Förster resonance energy transfer (FRET) mechanism strategy, a new dual-increasing emission proportional near-infrared (NIR) fluorescent probe Lay-1 was designed for fast benzoyl peroxide (BPO) detection in real food samples and biosystems. Specifically, it employed a naphthylimide derivative and a NIR fluorophore dicyanoisophorone derivative as the energy transfer donor and acceptor, respectively, and a phenylboronic acid (Ph-B(OH)2) as the responding group of BPO. In addition, the results exhibited that the fluorescence color of Lay-1 was changed from red to orange in the absence and the presence of BPO with a fast response time (â¼120 s), high sensitivity, and an excellent limit of detection as low as 60.8 nM. Impressively, Lay-1 has been successfully used for BPO detection in real food samples and biosystems with satisfactory results. Therefore, Lay-1 can be a robust molecular tool to further investigate the physiological and pathological function of BPO.
Assuntos
Peróxido de Benzoíla , Transferência Ressonante de Energia de Fluorescência , Corantes Fluorescentes , Corantes Fluorescentes/química , Peróxido de Benzoíla/análise , Peróxido de Benzoíla/química , Contaminação de Alimentos/análise , Análise de Alimentos , Limite de DetecçãoRESUMO
Adult acne vulgaris affects up to 43-51% of individuals. While there are numerous treatment options for acne including topical, oral, and energy-based approaches, benzoyl peroxide (BPO) is a popular over the counter (OTC) treatment. Although BPO monotherapy has a long history of efficacy and safety, it suffers from several disadvantages, most notably, skin irritation, particularly for treatment naïve patients. In this prospective, randomized, controlled, split-face study, we evaluated the comparative efficacy, safety, and tolerability of a novel 3-step azelaic acid, salicylic acid, and graduated retinol regimen versus a common OTC BPO-based regimen over 12 weeks. A total of 37 adult subjects with self-reported mild to moderate acne vulgaris were recruited. A total of 21 subjects underwent a 2-week washout period and completed the full study with 3 dropping out due to product irritation from the BPO routine, and 13 being lost to follow-up. Detailed tolerability surveys were conducted at Week 4. Additional surveys on tolerability and product preferences were collected monthly, at Week 4, Week 8, and Week 12. A blinded board-certified dermatologist objectively scored the presence and type of acne lesions (open or closed comedones, papules, pustules, nodules, and cysts) at baseline, Week 4, Week 8, and Week 12. Patients photographed themselves and uploaded the images using personal mobile phones. Detailed Week 4 survey results showed across 25 domains of user-assessed product performance, the novel routine outperformed the BPO routine in 19 (76%) which included domains in preference (e.g. "I would use this in the future) and performance ("my skin improved" and "helped my acne clear up faster"). Users of the novel routine reported less facial redness, itching, and burning, though differences did not reach statistical significance. In terms of efficacy, both products performed similarly, reducing total acne lesions by 36% (novel routine) and 40% (BPO routine) by Week 12. Overall, accounting for user preferences and tolerability the novel routine was more preferred than the BPO routine in 79% of domains (22/28). Differences in objective acne lesion reduction were not statistically significant (p = 0.97). In a randomized split-face study, a 3-step azelaic acid, salicylic acid, and graduated retinol regimen delivered similar acne lesion reduction, fewer user dropouts, greater user tolerability, and higher use preference compared to a 3-step BPO routine based in a cohort of participants with mild-to-moderate acne vulgaris.
Assuntos
Acne Vulgar , Peróxido de Benzoíla , Fármacos Dermatológicos , Ácidos Dicarboxílicos , Ácido Salicílico , Humanos , Acne Vulgar/tratamento farmacológico , Peróxido de Benzoíla/administração & dosagem , Peróxido de Benzoíla/efeitos adversos , Peróxido de Benzoíla/uso terapêutico , Adulto , Masculino , Feminino , Ácido Salicílico/administração & dosagem , Ácido Salicílico/efeitos adversos , Ácido Salicílico/uso terapêutico , Estudos Prospectivos , Adulto Jovem , Resultado do Tratamento , Método Duplo-Cego , Ácidos Dicarboxílicos/efeitos adversos , Ácidos Dicarboxílicos/administração & dosagem , Ácidos Dicarboxílicos/uso terapêutico , Fármacos Dermatológicos/efeitos adversos , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/uso terapêutico , Vitamina A/administração & dosagem , Vitamina A/efeitos adversos , Vitamina A/uso terapêutico , Administração Cutânea , Adolescente , Índice de Gravidade de Doença , Medicamentos sem Prescrição/administração & dosagem , Medicamentos sem Prescrição/efeitos adversos , Medicamentos sem Prescrição/uso terapêutico , Quimioterapia Combinada/métodosAssuntos
Peróxido de Benzoíla , Dermatite Alérgica de Contato , Dermatite Ocupacional , Dermatoses da Mão , Humanos , Dermatite Alérgica de Contato/etiologia , Dermatite Alérgica de Contato/diagnóstico , Dermatite Ocupacional/etiologia , Dermatite Ocupacional/diagnóstico , Dermatoses da Mão/induzido quimicamente , Dermatoses da Mão/etiologia , Peróxido de Benzoíla/efeitos adversos , Dermatoses Faciais/induzido quimicamente , Dermatoses Faciais/etiologia , Eczema/induzido quimicamente , Testes do Emplastro , Feminino , Adulto , Masculino , Clareadores/efeitos adversos , Púrpura/induzido quimicamente , Púrpura/etiologiaAssuntos
Acne Vulgar , Peróxido de Benzoíla , Leucemia Mieloide Aguda , Humanos , Acne Vulgar/tratamento farmacológico , Leucemia Mieloide Aguda/tratamento farmacológico , Peróxido de Benzoíla/uso terapêutico , Peróxido de Benzoíla/efeitos adversos , Feminino , Masculino , Adulto , Adulto Jovem , Fármacos Dermatológicos/efeitos adversos , Fármacos Dermatológicos/uso terapêutico , Adolescente , Medição de Risco , Estudos RetrospectivosRESUMO
Mapping the N-glycome of porcine sperm before and after sperm capacitation is important for understanding the rearrangement of glycoconjugates during capacitation. In this work, we characterized the N-glycome on the membranes of 18 pairs of fresh porcine sperm before capacitation and porcine sperm after capacitation by MALDI-MS (Matrix-assisted laser desorption/ionization-mass spectrometry). A total of 377 N-glycans were detected and a comprehensive N-glycome map of porcine sperm membranes before and after capacitation was generated, which presents the largest N-glycome dataset of porcine sperm cell membranes. Statistical analysis revealed a significantly higher level of high mannose glycosylation and a significantly lower level of fucosylation, galactosylation, and α-2,6-NeuAc after capacitation, which is further verified by flow cytometry and lectin blotting. This research reveals new insights into the relationship between N-glycosylation variations and sperm capacitation, including the underlying mechanisms of the capacitation process.
Assuntos
Peróxido de Benzoíla , Sêmen , Masculino , Suínos , Animais , Membranas , Membrana Celular , EspermatozoidesRESUMO
Purpose: Topical clindamycin, a lincosamide antibiotic, is commonly combined with benzoyl peroxide or a retinoid for acne vulgaris (AV) treatment. While oral and topical clindamycin carry warnings/contraindications regarding gastrointestinal (GI) adverse events (AEs), real-world incidence of GI AEs with topical clindamycin is unknown. This review provides background information and an overview of safety data of topical clindamycin for treating AV.Materials and Methods: Available safety data from published literature, previously unpublished worldwide pharmacovigilance data, and two retrospective cohort studies were reviewed.Results and Conclusions: According to pharmacovigilance data, the rate of GI adverse drug reactions with topical clindamycin-containing products was 0.000045% (64/141,084,533). Results from two retrospective medical record studies of patients with AV indicated that physicians prescribe topical clindamycin equally to patients with or without inflammatory bowel disease history, and that rates of pseudomembranous colitis in these patients were low. In 8 published pivotal clinical trials of topical clindamycin for AV, GI AEs were reported in 1.4% of participants. Limitations include under/inaccurate reporting of AEs or prescription data and limited generalizability. This review of published case reports, worldwide pharmacovigilance data, retrospective US prescription data, and clinical trials safety data demonstrates that the incidence of colitis in patients exposed to topical clindamycin is extremely low.
Assuntos
Acne Vulgar , Clindamicina , Humanos , Clindamicina/efeitos adversos , Estudos Retrospectivos , Acne Vulgar/tratamento farmacológico , Antibacterianos/efeitos adversos , Peróxido de Benzoíla/uso terapêuticoRESUMO
INTRODUCTION: Acne is a common skin disease with a high psychosocial burden, affecting mostly adolescents and youth worldwide. Management of acne is often challenged by cutaneous side effects that leads to therapeutic intolerance, poor compliance and impaired efficacy. MATERIALS AND METHODS: This was a single-centre, evaluatorblinded, split-face, randomised study investigating the effects of thermal spring water (TSW) in improving efficacy and tolerability of standard acne therapy. Total of 31 participants with mild-to-moderate acne were recruited and subjected to TSW spray to one side of the face 4 times daily for 6 weeks in addition to standard therapy. The other side received standard therapy only. RESULTS: Six (19.4%) males and 25 (80.6%) female with mean age 25.1±6.13 participated, 15 (48.4%) had mild acne while 16 (51.6%) had moderate acne. Seven (22.6%) were on oral antibiotics, 25 (80.6%) used adapalene, 6 (19.4%) tretinoin and 21 (67.7%) benzoyl peroxide. Skin hydration improved and better on spring water treated side with mean difference12.41±30.31, p = 0.04 at the forehead, 39.52±65.14, p < 0.01 at the cheek and 42.172±71.71, p < 0.01 at the jaw at week 6. Participants also report significant reduction in dryness at the treated side at week 6, mean difference 0.93±0.10, p < 0.001. TEWL, sebum and pH were comparable on both sides with no significant differences. Tolerability towards standard therapy improved as early week 2 with reduction of stinging following application of topical therapy (mean difference 0.62±1.43, p = 0.03), increase in skin feeling good (-1.79±1.70, p < 0.001) and skin suppleness (0.62±1.43, p < 0.001). These improvements were significantly maintained till week 6. Cardiff acne disability index significantly improved at week 6 (p<0.001) despite no significant changes in Comprehensive Acne Severity Scale score before and after treatment. CONCLUSION: TSW may have a role as an adjunct to standard acne therapy by improving hydration, acne disability index and tolerability towards standard topical treatment.
Assuntos
Acne Vulgar , Fontes Termais , Adolescente , Adulto , Feminino , Humanos , Masculino , Adulto Jovem , Acne Vulgar/tratamento farmacológico , Adapaleno/uso terapêutico , Peróxido de Benzoíla/uso terapêutico , Estudos Prospectivos , Resultado do TratamentoRESUMO
Rosacea, a chronic skin condition affecting millions of people in the USA, leads to significant social and professional stigmatization. Effective management strategies are crucial to alleviate symptoms and improve patients' quality of life. Encapsulated benzoyl peroxide 5% (E-BPO 5%) is a newly FDA-approved topical treatment for rosacea that shows promise in enhancing therapeutic response and minimizing skin irritation. This review aims to assess the role of recently FDA approved E-BPO 5% in the current treatment landscape for rosacea management, as it is not yet included in clinical guidelines that predominantly rely on older approved therapies. The review focuses on randomized controlled trials conducted in English-speaking adults. It evaluates the efficacy, safety, and tolerability of various US Food and Drug Administration (FDA)-approved agents used for rosacea treatment, including E-BPO cream, metronidazole gel, azelaic acid gel and foam, ivermectin cream, minocycline foam, oral doxycycline, brimonidine gel, and oxymetazoline HCl cream. Existing therapies have been effective in reducing papulopustular lesions and erythema associated with rosacea for many years. E-BPO 5% offers a promising addition to the treatment options due to its microencapsulation technology, which prolongs drug delivery time and aims to improve therapeutic response while minimizing skin irritation. Further research is necessary to determine the exact role of E-BPO 5% in the therapeutic landscape for rosacea. However, based on available evidence, E-BPO 5% shows potential as a valuable treatment option for managing inflammatory lesions of rosacea, and it may offer benefits to patients including: rapid onset of action, demonstrated efficacy by Week 2, excellent tolerability, and sustained long-term results for up to 52 weeks of treatment.
Assuntos
Fármacos Dermatológicos , Rosácea , Adulto , Humanos , Peróxido de Benzoíla/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Metronidazol/uso terapêutico , Qualidade de Vida , Rosácea/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
INTRODUCTION: Topical therapy is the mainstay treatment of acne, and topical retinoids such as tretinoin, tazarotene, and adapalene are recommended as the first-line therapy for mild to moderate acne. However, the cutaneous irritations may occur, and the dermocosmetics are recommended to prevent side effects of anti-acne drugs and adhere to treatment. Thus, this study aims to compare the efficacy and tolerability of ceramides and niacinamide-containing moisturizer (CCM) versus hydrophilic cream in combination with topical anti-acne treatment in mild to moderate acne vulgaris. METHODS: This was an 8-week, randomized, double-blinded, split face study in 40 patients assigned for topical anti-acne medications (5% benzoyl peroxide and 0.1% adapalene gel), then randomly applied CCM or hydrophilic cream. All patients were followed at week 0, 2, 4, and 8 for acne improvement, adverse reactions, biometric, and biophysical evaluation. RESULTS: CCM could significantly improve the non-inflammatory, inflammatory, and total acne lesions compared with hydrophilic cream after week 8 of treatment. Interestingly, there was an improvement of global worst score, hemoglobin index, melanin index, TEWL, skin hydration, sebum production, and skin surface pH, with no statistically significant differences between the two treatments. No serious side effects from clinical application of CCM and hydrophilic cream in mild to moderate acne vulgaris patients. CONCLUSION: Ceramide and niacinamide-containing moisturizer in combination with anti-acne medication can significantly improve acne lesions and decrease cutaneous irritations toward a satisfactory treatment outcome of mild to moderate acne vulgaris.
Assuntos
Acne Vulgar , Adapaleno , Administração Cutânea , Ceramidas , Fármacos Dermatológicos , Niacinamida , Índice de Gravidade de Doença , Creme para a Pele , Humanos , Acne Vulgar/tratamento farmacológico , Método Duplo-Cego , Niacinamida/administração & dosagem , Niacinamida/efeitos adversos , Feminino , Masculino , Creme para a Pele/administração & dosagem , Creme para a Pele/efeitos adversos , Ceramidas/administração & dosagem , Adulto Jovem , Adulto , Resultado do Tratamento , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/efeitos adversos , Adapaleno/administração & dosagem , Adolescente , Peróxido de Benzoíla/administração & dosagem , Peróxido de Benzoíla/efeitos adversos , Quimioterapia Combinada , Emolientes/administração & dosagem , Combinação de MedicamentosRESUMO
BACKGROUND: Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older. OBJECTIVE: The objective of this study was to provide evidence-based recommendations for the management of acne. METHODS: A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. RESULTS: This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements. LIMITATIONS: Analysis is based on the best available evidence at the time of the systematic review. CONCLUSIONS: These guidelines provide evidence-based recommendations for the management of acne vulgaris.